latest
Market/Novel Tech Articles

The European Commission (EC) approves “Luxturna” (voretigene neparvovec), a recently developed gene therapy product to treat Leber congenital amaurosis (RPE65 mutations)

A commercial gene therapy company, Spark Therapeutics (NASDAQ:ONCE), announced that Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has granted marketing authorization for “Luxturna” (voretigene neparvovec), the treatment of adult and pediatric patients with vision loss due to an inherited retinal dystrophy, Leber congenital amaurosis (LCA). Spark will manufacture and supply the […]

Read full story

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the exercise of an Allergan option to develop and commercialize “EDIT-101” – a CRISPR-based technology for the treatment of Leber Congenital Amaurosis type 10 (LCA10).  CRISPR (an acronym for “clustered regularly […]

Read full story

Novartis Q2 results emphasize transition to a full “100% medicines company”

Novartis AG (NYSE:NVS; SIX:NOVN), a Swiss-based biopharmaceutical company, has announced its second quarter results showing net sales of $13.2 billion for the period, of which net sales for ophthalmology products totaled $1.18 billion.  Novartis recently announced the sale of its stake in the GSK consumer healthcare joint venture for $13 billion, and its plan to […]

Read full story

Related Market/Novel Tech News